SCHEMBL4673105

SCHEMBL4673105

O=C(O)/C(O)=C/C(=O)c1csc(Cc2ccccn2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
ALDH1A1 P00352 4/20 0.40
KMT2A Q03164 2/20 0.40
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
SLC40A1 Q9NP59 3/20 0.40
RAB9A P51151 4/20 0.38
LMNA P02545 4/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
L3MBTL1 Q9Y468 3/20 0.38
NPC1 O15118 3/20 0.37
GAA P10253 1/20 0.37
MMP1 P03956 1/20 0.37
MMP2 P08253 1/20 0.37
MMP9 P14780 1/20 0.37
MMP13 P45452 1/20 0.37
POLB P06746 2/20 0.36
PTPRA P18433 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4673108 1.00 HDAC1 (0.42) HDAC1HDAC8HDAC6ALDH1A1KMT2A
SCHEMBL4678174 0.83 HDAC1 (0.60) HDAC1HDAC8HDAC6ALDH1A1KMT2A
SCHEMBL4678169 0.83 HDAC1 (0.60) HDAC1HDAC8HDAC6ALDH1A1KMT2A
SCHEMBL4676211 0.80 SLC40A1 (0.40) HDAC1HDAC8HDAC6ALDH1A1KMT2A
SCHEMBL4671490 0.80 SLC40A1 (0.37) HDAC1HDAC8HDAC6ALDH1A1KMT2A
SCHEMBL4174781 0.79 HDAC1 (0.45) HDAC1HDAC8HDAC6ALDH1A1KMT2A
SCHEMBL4670898 0.79 ALDH1A1 (0.39) ALDH1A1KMT2AKDM4EMEN1RAB9A
SCHEMBL4670896 0.79 ALDH1A1 (0.39) ALDH1A1KMT2AKDM4EMEN1RAB9A
SCHEMBL4673304 0.79 HDAC1 (0.48) HDAC1HDAC8HDAC6ALDH1A1KMT2A
SCHEMBL4673302 0.79 HDAC1 (0.48) HDAC1HDAC8HDAC6ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 HDAC1 250/4885HDAC8 167/4885HDAC6 1000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.